At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Assessment of the Efficacy in Reduction of Nasal Polyp Size in Patients With Nasal Polyposis and Concomitant Asthma.
In Brief
A Phase 3 clinical trial evaluating Fevipiprant 150 mg, Fevipiprant 450 mg, and 1 other intervention for Nasal Polyps. Completed, enrolled 98 participants across 25 sites in 9 countries.
Detailed Summary
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years) patients with nasal polyposis and concomitant asthma.
Study Details
Timeline
Interventions
Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
Placebo once daily administered orally as tablet